Entera Bio (ENTX) Non-Current Debt (2017 - 2026)
Entera Bio's (ENTX) quarterly Non-Current Debt came in at $567000.0 in Q1 2026, up 10.1% YoY from $515000.0 in Q1 2025, and up 44.27% on a QoQ basis from $393000.0 in Q4 2025.
Entera Bio (ENTX) Non-Current Debt (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 3 years of Non-Current Debt data on file, last reported at $567000.0 in Q1 2026.
- Quarterly Non-Current Debt rose 10.1% year-over-year to $567000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $567000.0 (up 10.1% YoY) and the FY2025 annual result came in at $393000.0, changed N/A from the prior year.
- Non-Current Debt climbed to $567000.0 in Q1 2026, from $393000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $567000.0 in Q1 2026 to a low of $393000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 8.96 Bn |
| 10 | Entera Bio | 166.99 Mn | 155.68 Mn | - | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284,000.00 |
| Mar 31, 2026 | 567,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 524,000.00 |
| Mar 31, 2025 | 515,000.00 |
| Dec 31, 2017 | 3.89 Mn |